SCHEMBL19511908

SCHEMBL19511908

COC(=O)c1cc(C(C)=O)cn(-c2ccccc2)c1=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.60
KDM4E B2RXH2 2/20 0.60
LMNA P02545 2/20 0.60
HSD17B10 Q99714 1/20 0.56
GABRA1 P14867 3/20 0.51
GABRG2 P18507 3/20 0.51
GABRB3 P28472 3/20 0.51
GABRA3 P34903 3/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
NR4A2 P43354 1/20 0.51
GAA P10253 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.47
GABRA2 P47869 2/20 0.45
GABRA5 P31644 1/20 0.45
MAPK1 P28482 1/20 0.45
BRD4 O60885 1/20 0.43
FGFR1 P11362 2/20 0.43
SRC P12931 1/20 0.43
MAPT P10636 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23147126 0.86 KMT2A (0.60) ALDH1A1KDM4ELMNAHSD17B10GABRA1
SCHEMBL19511938 0.85 KDM4E (0.54) ALDH1A1KDM4ELMNAHSD17B10MEN1
SCHEMBL28430420 0.83 KDM4E (0.63) ALDH1A1KDM4ELMNAHSD17B10GABRA1
SCHEMBL198437 0.82 ALDH1A1 (0.62) ALDH1A1KDM4ELMNAHSD17B10GABRA1
SCHEMBL19511981 0.81 ALDH1A1 (0.52) ALDH1A1KDM4ELMNAHSD17B10GABRA1
SCHEMBL18044628 0.80 LMNA (0.59) ALDH1A1KDM4ELMNAGABRA1GABRG2
SCHEMBL1883282 0.77 ALDH1A1 (0.75) ALDH1A1KDM4ELMNAHSD17B10KMT2A
SCHEMBL28433852 0.77 HSD17B10 (0.66) ALDH1A1KDM4ELMNAHSD17B10MEN1
SCHEMBL1136978 0.75 ALDH1A1 (0.60) ALDH1A1KDM4ELMNAHSD17B10GABRA1
SCHEMBL1885385 0.75 GABRG2 (0.56) ALDH1A1KDM4ELMNAGABRA1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3239147-B1 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO (JP) 2019-08-28 EP disclosed
US-10208034-B2 Quinoline derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2019-02-19 US disclosed
US-20170349583-A1 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2017-12-07 US disclosed
EP-3239147-A1 QUINOLINE DERIVATIVE Ono Pharmaceutical Co., Ltd. (JP) 2017-11-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170349583-A1 QUINOLINE DERIVATIVE FLT3, AXL, ABL1 ALDH1A1 3586/4885KDM4E 972/4885LMNA 4461/4885
US-10208034-B2 Quinoline derivative FLT3, AXL, ABL1 ALDH1A1 3586/4885KDM4E 972/4885LMNA 4461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.